Fibromyalgia Epidemiology Forecast

DelveInsight's 'Fibromyalgia - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Fibromyalgia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Fibromyalgia Understanding

The DelveInsight Fibromyalgia epidemiology report gives a thorough understanding of the Fibromyalgia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Fibromyalgia in the US, Europe, and Japan. The report covers the detailed information of the Fibromyalgia epidemiology scenario in seven major countries (US, EU5, and Japan).


Fibromyalgia Epidemiology Perspective by DelveInsight

The Fibromyalgia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Fibromyalgia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Fibromyalgia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Fibromyalgia Detailed Epidemiology Segmentation

The Fibromyalgia epidemiology covered in the report provides historical as well as forecasted Fibromyalgia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Fibromyalgia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Fibromyalgia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Fibromyalgia Epidemiology Report and Model provide an overview of the risk factors and global trends of Fibromyalgia in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Fibromyalgia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Fibromyalgia
  • The report provides the segmentation of the Fibromyalgia epidemiology


Report Highlights

  • 11-Year Forecast of Fibromyalgia epidemiology
  • 7MM Coverage
  • Total Cases of Fibromyalgia
  • Total Cases of Fibromyalgia according to segmentation
  • Diagnosed cases of Fibromyalgia


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Fibromyalgia?
  • What are the key findings pertaining to the Fibromyalgia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Fibromyalgia across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Fibromyalgia?
  • What are the currently available treatments of Fibromyalgia?


Reasons to buy

  • The Fibromyalgia Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Fibromyalgia market
  • Quantify patient populations in the global Fibromyalgia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Fibromyalgia therapeutics in each of the markets covered
  • Understand the magnitude of Fibromyalgia population by its epidemiology
  • The Fibromyalgia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Fibromyalgia

3. Fibromyalgia: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Fibromyalgia Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Fibromyalgia Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Fibromyalgia Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Fibromyalgia Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Fibromyalgia Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Fibromyalgia Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Fibromyalgia Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Fibromyalgia Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Fibromyalgia Treatment and Management

6.2. Fibromyalgia Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Fibromyalgia Epidemiology in 7MM (2017-2030)

Table 2 Fibromyalgia Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Fibromyalgia Epidemiology in the United States (2017-2030)

Table 4 Fibromyalgia Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Fibromyalgia Epidemiology in Germany (2017-2030)

Table 6 Fibromyalgia Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Fibromyalgia Epidemiology in France (2017-2030)

Table 8 Fibromyalgia Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Fibromyalgia Epidemiology in Italy (2017-2030)

Table 10 Fibromyalgia Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Fibromyalgia Epidemiology in Spain (2017-2030)

Table 12 Fibromyalgia Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Fibromyalgia Epidemiology in the United Kingdom (2017-2030)

Table 14 Fibromyalgia Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Fibromyalgia Epidemiology in Japan (2017-2030)

Table 16 Fibromyalgia Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Fibromyalgia Epidemiology in 7MM (2017-2030)

Figure 2 Fibromyalgia Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Fibromyalgia Epidemiology in the United States (2017-2030)

Figure 4 Fibromyalgia Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Fibromyalgia Epidemiology in Germany (2017-2030)

Figure 6 Fibromyalgia Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Fibromyalgia Epidemiology in France (2017-2030)

Figure 8 Fibromyalgia Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Fibromyalgia Epidemiology in Italy (2017-2030)

Figure 10 Fibromyalgia Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Fibromyalgia Epidemiology in Spain (2017-2030)

Figure 12 Fibromyalgia Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Fibromyalgia Epidemiology in the United Kingdom (2017-2030)

Figure 14 Fibromyalgia Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Fibromyalgia Epidemiology in Japan (2017-2030)

Figure 16 Fibromyalgia Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • Fibromyalgia Epidemiology
  • Fibromyalgia
  • Fibromyalgia Pipeline
  • Fibromyalgia Companies
  • Fibromyalgia prevalent population
  • Fibromyalgia incident population
  • Fibromyalgia patients diagnosed
  • Fibromyalgia treatment algorithm

Forward to Friend

Need A Quote